Investors Alert: Potential Class Action Against Aquestive Therapeutics, Inc. for Misleading Statements

AQST Shareholder Alert: Join the Class Action

This article is directed towards investors who experienced losses while holding shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) during a specific time frame. Following an announcement from the company that raised concerns over its new drug application for Anaphylm (Dibutepinephrine) sublingual film, many shareholders are discovering their options for legal recourse.

Background on the Company and the Allegations

Aquestive Therapeutics is a notable name in the pharmaceutical industry, focusing on innovative drug delivery systems. However, issues have arisen regarding the treatment of shareholders and the transparency of information regarding crucial applications to the FDA.

From June 16, 2025, to January 8, 2026, shareholders who purchased AQST shares may be eligible to participate in a class action lawsuit. Allegations brought forth in a complaint against the company suggest that it provided overly optimistic statements while simultaneously concealing significant adverse facts. This includes a reported deficiency identified by the FDA that hindered discussions regarding Anaphylm’s labeling.

Following this news, the company’s stock price plummeted significantly. On January 9, 2026, the market observed a drastic decline from $6.21 to $3.91 per share—a staggering decrease of more than 37% in just one day. Such a drop has prompted many affected investors to consider their legal options.

Next Steps for Shareholders

If you are a shareholder who experienced losses during the specified period, it is crucial not to delay in pursuing your rights. The Gross Law Firm, which handles numerous class action lawsuits, has called upon stakeholders to register for possible lead plaintiff appointments. While you do not need to be a lead plaintiff to recover losses, taking prompt action is advised.

To assist investors, the firm has set a deadline of May 4, 2026, for those wishing to move forward as lead plaintiffs. Registering provides necessary updates throughout the case's lifecycle through a dedicated monitoring system.

Additionally, stakeholders are warned of the implications surrounding the FDA's response to the Anaphylm NDA. The letter that raised alarm regarding potential deficiencies has naturally caused alarm for investors and calls into question the company's honesty in communications.

Why Engage the Gross Law Firm?

The Gross Law Firm stands out due to its reputation as a nationally recognized class action firm, dedicated to safeguarding investors' rights affected by corporate misdeeds. The firm’s mission focuses on ensuring responsible business operations and advocating for transparency in corporate communications—missions that resonate deeply with affected investors.

For those who have suffered losses in this scenario, participating in legal actions not only aids personal recovery efforts but also helps promote accountability among corporate entities.

Contact Information: For inquiries or to register for the class action suit, contact the Gross Law Firm’s New York office at (646) 453-8903 or visit their website for further information. Following through could be a key step in recovering losses.

Conclusion

In conclusion, shareholders of Aquestive Therapeutics, Inc. should act swiftly in light of the recent happenings concerning the company. Those who purchased shares during the designated time frame should consider engaging with the Gross Law Firm to explore their legal options and ensure their voices are heard in the imminent class action lawsuit.